Intellia's single-dose CRISPR therapy slashed hereditary angioedema attacks by 87% in a pivotal Phase 3 trial, with 62% of patients going completely attack-free. One injection that permanently edits your DNA while it's still inside you: the future of gene editing just got very real.
Imagine living with a condition where your body randomly attacks itself. Your face swells. Your throat closes. Your abdomen seizes with pain so severe it sends you to the ER. Now imagine someone tells you a single IV drip could make it stop, possibly forever.
That's the promise Intellia Therapeutics just delivered data on. And the numbers are stunning.
The Disease Nobody Talks About
Hereditary angioedema (HAE) is a rare genetic disorder. The body produces too much of a molecule called bradykinin, which causes sudden, unpredictable swelling episodes. These attacks can hit the face, hands, feet, gut, or airway. Laryngeal attacks (the throat ones) can be fatal.
Current treatments work, but they're a grind. Patients inject themselves with antibodies every two to four weeks, pop daily pills, or keep emergency medications on hand for breakthrough episodes. Even with all of that, roughly 40% of attacks still go untreated. Think of it like having a fire extinguisher in every room but still watching small fires burn because you can't get to them fast enough.
The global HAE treatment market sits somewhere between $3 billion and $7.8 billion in 2025, depending on whose estimate you trust. It's big, it's growing, and it's ripe for disruption.
One Infusion, 87% Fewer Attacks
Intellia's therapy, called lonvoguran ziclumeran (mercifully nicknamed "lonvo-z"), takes a radically different approach. Instead of managing symptoms on a recurring schedule, it uses CRISPR gene editing to permanently rewrite the source code of the problem.
The Phase 3 trial, called HAELO, enrolled 80 patients: 52 received lonvo-z and 28 got placebo. Over a six-month evaluation window, patients on lonvo-z experienced a mean of 0.19 attacks per month compared to 1.79 for placebo. That's an 87% reduction in attack rate, with a p-value below 0.0001.
But the headline number, impressive as it is, undersells the story.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A full 62% of treated patients were completely attack-free and off all other HAE therapy for the entire six months. Only 11% of placebo patients could say the same. For the 38% of treated patients who did still have some attacks, their rate dropped by 72% on average.
Every single treated patient saw some improvement. Every one.
How a Single IV Drip Edits Your DNA
The science here reads like science fiction, but it's actually elegant in its simplicity.
Lonvo-z is delivered through a standard IV infusion. Inside the bag: tiny fat bubbles called lipid nanoparticles (LNPs) carrying two pieces of RNA. One encodes the Cas9 protein, which acts like molecular scissors. The other is a guide RNA that tells those scissors exactly where to cut.
Once infused, the LNPs naturally travel to the liver (fat particles love the liver; it's basically their favorite restaurant). They get swallowed up by liver cells, where the RNA cargo goes to work. The Cas9 protein forms, pairs with its guide, enters the cell's nucleus, and snips a gene called KLKB1.
KLKB1 makes prekallikrein, the protein that eventually becomes kallikrein, which produces the bradykinin responsible for HAE attacks. Cut the gene, stop the protein, stop the cascade. The cell tries to repair the cut but does so sloppily, introducing errors that permanently disable the gene.
The CRISPR machinery is active for only a short time. But the edit? That's written into the DNA of long-lived liver cells. It sticks around.
Phase 1/2 data backs up the durability claim: patients tracked for up to three years maintained attack reductions of 96% or more from baseline. Thirty-one out of 32 patients in long-term follow-up remained attack-free and off preventive therapy.
Clean Safety, High Stakes
For a therapy that permanently alters human DNA, safety is everything. And so far, lonvo-z's profile looks remarkably clean.
In Phase 3, Intellia reported no serious or severe treatment-related adverse events in the treatment arm. The most common side effects from earlier studies were infusion-related reactions, fatigue, and headache, all mild to moderate. One patient had a temporary bump in liver enzymes that resolved on its own. One serious event across the entire program (a blood clot a full year after treatment, in a patient with pre-existing risk factors) was not clearly linked to the therapy.
That said, Intellia's broader platform hasn't been trouble-free. A separate Phase 3 trial for a different CRISPR therapy (NTLA-2001, targeting a heart condition) reported a serious liver enzyme elevation that spooked investors and landed the program on clinical hold. That episode is a reminder: the technology is powerful, but the margin for error with permanent gene editing is razor-thin.
Wall Street Is Interested but Nervous
Analyst reactions to the HAE data split along a predictable fault line. The data itself? Universally praised. The platform risk? That's where opinions diverge.
Leerink Partners bumped its probability of success for lonvo-z to 90% and raised its price target to $35. Citizens valued the HAE program alone at $18 per share, notably above where the stock was trading (around $13). Chardan and TD Cowen maintained Buy ratings.
On the cautious side, Baird actually cut its target to $18, arguing that strong HAE data "was not sufficient to mitigate the risks of in vivo gene editing." BofA raised its target slightly but kept a Neutral stance.
The consensus? The HAE asset is a winner. Whether it's enough to carry the whole company past platform-level safety concerns remains the open question.
The Road to Your Medicine Cabinet
Intellia isn't waiting around. The company initiated a rolling BLA submission (essentially filing the FDA application in installments) back in April 2026, enabled by a special designation called RMAT that the agency reserves for regenerative therapies with serious potential. The full application should be complete by late 2026, with a targeted U.S. launch in the first half of 2027.
If approved, lonvo-z would be the first in vivo CRISPR gene-editing therapy for a chronic disease. Not an ex vivo treatment where cells are edited in a lab and put back (like sickle cell therapies). An actual injection that edits your genes while they're still inside you.
Why This Matters Beyond HAE
The liver makes hundreds of proteins that circulate through your blood. Many of them cause disease when they malfunction. Lonvo-z's playbook (LNP to liver, CRISPR cuts a gene, problem solved) is a template that could theoretically apply to dozens of conditions.
Competitors are already chasing that vision. CRISPR Therapeutics has multiple liver-targeted programs hitting cardiovascular targets like ANGPTL3 and LPA. Verve Therapeutics is using a related approach called base editing to silence PCSK9 for cholesterol management. The race to own "one shot, one cure" for liver-expressed diseases is heating up fast.
But Intellia got there first with pivotal data. And in biotech, being first with clean Phase 3 results in a validated market is a very good place to be.
One shot. Eighty-seven percent fewer attacks. Sixty-two percent of patients completely free. If this is what the future of medicine looks like, it's arriving faster than most people expected.
Clinical & Regulatory
4 min read
Trodelvy Just Jumped the Line in Breast Cancer Treatment
The FDA just moved Gilead's Trodelvy from last-resort to first-choice in triple-negative breast cancer, the deadliest breast cancer subtype. It's a seismic shift for patients, a multi-billion-dollar opportunity for Gilead, and a surprisingly friendly outcome for Merck's Keytruda.
